Higher psoriasis drug doses show promise in small trial
Disease control
Completed
This pilot study tested higher-than-standard doses of risankizumab in 20 adults with moderate-to-severe plaque psoriasis. The goal was to see if higher doses could better reduce certain skin immune cells (resident memory T cells) and improve skin clearance. The study was complete…
Phase: PHASE2 • Sponsor: Oregon Medical Research Center • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC